RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Addex Therapeutics Stock

Addex Therapeutics Equity 2024

Addex Therapeutics Equity

0 CHF

Ticker

ADXN.SW

ISIN

CH0029850754

WKN

A0MSH6

In 2024, Addex Therapeutics's equity was 0 CHF, a -100% increase from the 4.91 M CHF equity in the previous year.

Addex Therapeutics Aktienanalyse

What does Addex Therapeutics do?

Addex Therapeutics Ltd is a biotechnology company focused on the discovery and development of novel oral drugs. The company was founded in Geneva, Switzerland in 2002 and has made significant progress in researching drug candidates for various conditions such as schizophrenia, ADHD, migraines, and other central nervous system disorders. Addex Therapeutics' business model is based on the development of modulating therapeutics that specifically influence cellular signaling pathways. The company utilizes the proven AMC platform (Addex Modulation Cloning) to quickly and efficiently identify and validate specific receptor projects. Additionally, the company has a wide range of research and development programs, from preclinical to clinical study phases. Addex Therapeutics Ltd specializes in three therapeutic areas: neurological, immunological, and anti-inflammatory diseases. Within these areas, the company develops various drugs that specifically target certain receptors and provide help and relief for various conditions. One of Addex's most significant medical projects currently is the ADX71149 drug candidate for the treatment of schizophrenia and autism. Addex Therapeutics Ltd's products include a variety of neuromodulators and other drug candidates. The company has filed numerous international patents and maintains a high standard in the pharmaceutical development industry. The key product candidates are: - ADX10059: A new drug used in the treatment of migraines and dizziness. ADX10059 is a P2X3 receptor antagonist that can help suppress the transmission of pain signals in the central nervous system. - ADX88178: A drug candidate targeting the GABA-B receptor. This receptor is central to deep-seated pain and extrapyramidal side effects of classic antipsychotics. - ADX71943: A drug candidate used in the treatment of neuropsychiatric disorders such as Rett syndrome and ADHD. ADX71943 is a selective agonist of the GABA-B receptor, modulating the release of neurotransmitters in the brain. Overall, Addex Therapeutics offers an extensive product range and carries out a variety of projects in different stages of development. The company's core competency lies in modulators that can control specific receptors (neurotransmitter or hormone receptors). Addex Therapeutics Ltd is headquartered in Geneva, Switzerland, but also has branches in New York and San Francisco. The company focuses on expanding its competitiveness in the field of novel drugs and expanding its portfolio of products and international customers. Addex Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Addex Therapeutics's Equity

Addex Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Addex Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Addex Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Addex Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Addex Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Addex Therapeutics stock

What is the equity of Addex Therapeutics this year?

Addex Therapeutics has equity of 0 CHF this year.

What was the equity of Addex Therapeutics compared to the previous year?

The equity of Addex Therapeutics has increased/decreased by -100% decreased compared to the previous year.

What impact does a high equity have on investors of Addex Therapeutics?

A high equity is advantageous for investors of Addex Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Addex Therapeutics?

A low equity can be a risk for investors of Addex Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Addex Therapeutics affect the company?

An increase in equity of Addex Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Addex Therapeutics affect the company?

A reduction in equity of Addex Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Addex Therapeutics?

Some factors that can affect the equity of Addex Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Addex Therapeutics so important for investors?

The equity of Addex Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Addex Therapeutics take to change the equity?

To change equity, Addex Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Addex Therapeutics pay?

Over the past 12 months, Addex Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Addex Therapeutics is expected to pay a dividend of 0 CHF.

What is the dividend yield of Addex Therapeutics?

The current dividend yield of Addex Therapeutics is .

When does Addex Therapeutics pay dividends?

Addex Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Addex Therapeutics?

Addex Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Addex Therapeutics?

For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.

In which sector is Addex Therapeutics located?

Addex Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Addex Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Addex Therapeutics from 9/11/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 9/11/2024.

When did Addex Therapeutics pay the last dividend?

The last dividend was paid out on 9/11/2024.

What was the dividend of Addex Therapeutics in the year 2023?

In the year 2023, Addex Therapeutics distributed 0 CHF as dividends.

In which currency does Addex Therapeutics pay out the dividend?

The dividends of Addex Therapeutics are distributed in CHF.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Addex Therapeutics

Our stock analysis for Addex Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Addex Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.